These observations raise the possibility the ligand GLP-1(736) itself, by increasing intracellular cAMP, exerts a stimulatory rather than an inhibitory effect on glucagon secretion [57]
While direct head-to-head trials have not been conducted, we can examine the Phase 2 results for each medication to understand their relative efficacy
Overall treatment discontinuation rates were similar across the retatrutide and placebo treatment arms
Sorour NE, Abd El-Kareem HM, Ibrahim AE, Salem RM
Research-Use Dosing Conventions (Laboratory Settings Only) The figures below are reported to help interpret the literature and the approved label
Clinical trials show nausea occurs in roughly 20 to 30 percent of patients at starting doses, and the severity ranges from mild queasiness to more pronounced symptoms that usually resolve within a week